secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001493152-23-043794
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MyMD Pharma gains FDA clearance for Phase 2 trial of oral MYMD-1 in rheumatoid arthritis
--------------------------------------------------------------------------------

- FDA cleared IND for Phase 2 trial of oral MYMD-1 (TNF-α inhibitor) in rheumatoid arthritis.
- Trial planned for Q1 2024; will enroll ~60 patients with active RA at 1050 mg oral dose.
- Preclinical data: MYMD-1 reduced disease severity by 47% vs 37% for Enbrel (etanercept).
- MYMD-1 could become first FDA-approved orally administered TNF-α inhibitor for RA.
- RA affects ~1.5M Americans with annual societal cost estimated over $40 billion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223043794/0001493152-23-043794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223043794/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-043794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer